The DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.
GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women
Abstract
CONTEXT: Recent studies indicate that glucagon-like peptide (GLP)-1 regulates bone turnover, but the effects of GLP-1 receptor agonists (GLP-1 RAs) on bone in obese weight-reduced individuals are unknown. OBJECTIVE: To investigate the role of GLP-1 RAs on bone formation and weight loss-induced bone mass reduction. DESIGN: Randomized control study. SETTING: Outpatient research hospital clinic. PARTICIPANTS: Thirty-seven healthy obese women with body mass index of 34 ± 0.5 kg/m(2) and age 46 ± 2 years. INTERVENTION: After a low-calorie-diet-induced 12% weight loss, participants were randomized to treatment with or without administration of the GLP-1 RA liraglutide (1.2 mg/d) for 52 weeks. In case of weight gain, up to two meals per day could be replaced with a low-calorie-diet product to maintain the weight loss. MAIN OUTCOME MEASURES: Total, pelvic, and arm-leg bone mineral content (BMC) and bone markers [C-terminal telopeptide of type 1 collagen (CTX-1) and N-terminal propeptide of type 1 procollagen (P1NP)] were investigated before and after weight loss and after 52-week weight maintenance. Primary endpoints were changes in BMC and bone markers after 52-week weight maintenance with or without GLP-1 RA treatment. RESULTS: Total, pelvic, and arm-leg BMC decreased during weight maintenance in the control group (P < .0001), but not significantly in the liraglutide group. Thus, total and arm-leg BMC loss was four times greater in the control group compared to the liraglutide group (estimated difference, 27 g; 95% confidence interval, 5-48; P = .01), although the 12% weight loss was maintained in both groups. In the liraglutide group, the bone formation marker P1NP increased by 16% (7 ± 3 μg/L) vs a 2% (-1 ± 4 μg/L) decrease in the control group (P < .05). The bone resorption marker CTX-1 collagen did not change during the weight loss maintenance phase. CONCLUSIONS: Treatment with a long-acting GLP-1 RA increased bone formation by 16% and prevented bone loss after weight loss obtained through a low-calorie diet, supporting its role as a safe weight-lowering agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In euglycemic individuals, liraglutide increased procollagen type I N-terminal propeptide (P-PINP) levels by 16%, compared with a 2% decrease in the placebo group [42].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [42]
In the citing paper
“Treatment with liraglutide has been shown to increase bone formation in body weight-reduced obese women when compared to placebo (14).”
In the citing paper
“The reduction in PINP in the exenatide-treated group contrasts a previously reported increase of PINP in obese women, who experienced a 12% body weight reduction after 12 months of liraglutide treatment (14).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationBone “mass” and the “mechanostat”: A proposal
Frost, H. M. (1987) · The Anatomical Record · doi:10.1002/ar.1092190104 · Cited by 2,132
Systematic Review of Type 1 and Type 2 Diabetes Mellitus and Risk of Fracture
Janghorbani, M., van Dam, R. M., Willett, W. C., & Hu, F. B. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm106 · Cited by 1,223
for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke, Y. K., Singh, S., & Furberg, C. D. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080486 · Cited by 553
Mechanical and textural properties of pelvic trabecular bone
Dalstra, M., Huiskes, R., Odgaard, A., & van Erning, L. (1993) · Journal of Biomechanics · doi:10.1016/0021-9290(93)90014-6 · Cited by 361
Bone Metabolism in Obesity and Weight Loss
Shapses, S. A., & Sukumar, D. (2012) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104655 · Cited by 358
Role of Gastrointestinal Hormones in Postprandial Reduction of Bone Resorption
Henriksen, D. B., Alexandersen, P., Bjarnason, N. H., Vilsbøll, T., Hartmann, B., Henriksen, E. E., Byrjalsen, I., Krarup, T., Holst, J. J., & Christiansen, C. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.12.2180 · Cited by 331
Self-citationFærch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321
Self-citation
Research works printed but not linked: 1
- Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gas- trointestinal hormones in postprandial reduction of bone resorp- tion. J Bone Miner Res. 2003;18(12):2180 -2189.
Cited by
Sorted by citations
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Self-citationIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Hygum, K., Starup‐Linde, J., Harsløf, T., Vestergaard, P., & Langdahl, B. L. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0652 · Cited by 334
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217
Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management
Paschou, S. Α., Dede, A. D., Anagnostis, P. G., Vryonidou, A., Morganstein, D. L., & Goulis, D. G. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00042 · Cited by 206
BMI and BMD: the potential interplay between obesity and bone fragility
Palermo, A., Tuccinardi, D., Defeudis, G., Watanabe, M., D’Onofrio, L., Lauria Pantano, A., Napoli, N., Pozzilli, P., & Manfrini, S. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13060544 · Cited by 197
The Interplay Between Bone and Glucose Metabolism
Cipriani, C., Colangelo, L., Santori, R., Renella, M., Mastrantonio, M., Minisola, S., & Pepe, J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00122 · Cited by 202
Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties
Picke, A., Campbell, G. M., Napoli, N., Hofbauer, L. C., & Rauner, M. (2019) · Endocrine Connections · doi:10.1530/ec-18-0456 · Cited by 207
Jensen, S. B. K., Sørensen, V., Sandsdal, R. M., Lehmann, E. W., Lundgren, J. R., Juhl, C. R., Janus, C., Ternhamar, T., Stallknecht, B. M., Holst, J. J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.16775 · Cited by 155
Self-citationCentrally Acting Agents for Obesity: Past, Present, and Future
Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151
Savvidis, C., Tournis, S., & Dede, A. D. (2018) · HORMONES · doi:10.1007/s42000-018-0018-4 · Cited by 155
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Insulin resistance and bone: a biological partnership
Conte, C., Epstein, S., & Napoli, N. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1101-7 · Cited by 130
Assessment and treatment of osteoporosis and fractures in type 2 diabetes
Sheu, A., Greenfield, J. R., & White, C. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.02.006 · Cited by 119
Hansen, M. S., Wölfel, E. M., Jeromdesella, S., Møller, J.-J. K., Ejersted, C., Jørgensen, N. R., Eastell, R., Hansen, S. G., & Frost, M. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102624 · Cited by 115
Self-citationThe Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms
Zhao, C., Liang, J., Yang, Y., Yu, M., & Qu, X. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00098 · Cited by 124
Liu, Y., Ruan, B., Jiang, H., Le, S., Liu, Y., Ao, X., Huang, Y., Shi, X., Xue, R., Fu, X., et al. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.04.017 · Cited by 121
The crosstalk between bone remodeling and energy metabolism: A translational perspective
Karsenty, G., & Khosla, S. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.04.010 · Cited by 113
Cheng, L., Hu, Y., Li, Y.-Y., Cao, X., Bai, N., Lu, T., Li, G., Li, N., Wang, A., & Mao, X. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3168 · Cited by 112
Pathophysiology of Bone Fragility in Patients with Diabetes
Palermo, A., D'Onofrio, L., Buzzetti, R., Manfrini, S., & Napoli, N. (2017) · Calcified Tissue International · doi:10.1007/s00223-016-0226-3 · Cited by 94
Schiellerup, S. P., Skov‐Jeppesen, K., Windeløv, J. A., Svane, M. S., Holst, J. J., Hartmann, B., & ROSENKILDE, M. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00075 · Cited by 110
Self-citationGLP-1a: Going beyond Traditional Use
Laurindo, L. F., Barbalho, S. M., Guiguer, E. L., da Silva Soares de Souza, M., de Souza, G. A., Fidalgo, T. M., Araújo, A. C., de Souza Gonzaga, H. F., de Bortoli Teixeira, D., de Oliveira Silva Ullmann, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020739 · Cited by 102
Romero-Díaz, C., Duarte‐Montero, D., Gutiérrez-Romero, S. A., & Mendivil, C. O. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00964-1 · Cited by 107
Liraglutide for Type 2 diabetes and obesity: a 2015 update
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1054810 · Cited by 101
Self-citationChristensen, M., Lund, A., Calanna, S., Jørgensen, N. R., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01949 · Cited by 101
Self-citationDiabetes pharmacotherapy and effects on the musculoskeletal system
Kalaitzoglou, E., Fowlkes, J. L., Popescu, I. R., & Thrailkill, K. M. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3100 · Cited by 103
Hygum, K., Starup‐Linde, J., & Langdahl, B. L. (2019) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2019.05.001 · Cited by 87
Parkinson's disease in women: Mechanisms underlying sex differences
Vaidya, B., Dhamija, K., Guru, P., & Sharma, S. S. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173862 · Cited by 88
Cai, T.-T., Li, H.-Q., Jiang, L.-L., Wang, H.-Y., Luo, M.-H., Su, X.-F., & Ma, J.-H. (2021) · BioMed Research International · doi:10.1155/2021/3361309 · Cited by 84
Bone health in diabetes and prediabetes
Costantini, S., & Conte, C. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i8.421 · Cited by 84
Hygum, K., Harsløf, T., Jørgensen, N. R., Rungby, J., Pedersen, S. B., & Langdahl, B. L. (2019) · Bone · doi:10.1016/j.bone.2019.115197 · Cited by 77
Self-citationThe Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review
Daniilopoulou, I., Vlachou, E., Lambrou, G. I., Ntikoudi, A., Dokoutsidou, E., Fasoi, G., Govina, O., Kavga, A., & Tsartsalis, A. N. (2022) · Medicina · doi:10.3390/medicina58020224 · Cited by 74
Lim, S. K., Kim, K. M., & Nauck, M. A. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.01.011 · Cited by 70
Bergmann, N. C., Lund, A., Gasbjerg, L. S., Jørgensen, N. R., Jessen, L., Hartmann, B., Holst, J. J., Christensen, M., Vilsbøll, T., & Knop, F. K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00008 · Cited by 65
Self-citationNovel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists
Mabilleau, G., Pereira, M., & Chenu, C. (2017) · Journal of Endocrinology · doi:10.1530/joe-17-0278 · Cited by 66
The role of endogenous GIP and GLP-1 in postprandial bone homeostasis
Helsted, M. M., Gasbjerg, L. S., Lanng, A. R., Bergmann, N. C., Stensen, S., Hartmann, B., Christensen, M., Holst, J. J., Vilsbøll, T., ROSENKILDE, M. M., et al. (2020) · Bone · doi:10.1016/j.bone.2020.115553 · Cited by 63
Self-citationYang, L., Yang, J., Pan, T., & Zhong, X. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01034-5 · Cited by 57
Onoviran, O. F., Li, D., Smith, S. T., & Raji, M. A. (2019) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319862691 · Cited by 64
Marrano, N., Biondi, G., Borrelli, A., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2021) · Biomolecules · doi:10.3390/biom11020286 · Cited by 56
Du, X., Zhang, H., Zhang, W., Wang, Q., Wang, W., Ge, G., Bai, J., Guo, X., Zhang, Y., Jiang, X., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105732 · Cited by 55
The effects of GLP-1 agonists on musculoskeletal health and orthopedic care
Gatto, A., Liu, K., Milan, N., & Wong, S. (2025) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-025-09978-3 · Cited by 55
Periodontitis and mechanisms of cardiometabolic risk: Novel insights and future perspectives
Mesa, F., Magán‐Fernández, A., Castellino, G., Chianetta, R., Nibali, L., & Rizzo, M. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.12.001 · Cited by 51
Herrou, J., Mabilleau, G., Lecerf, J.-M., Thomas, T., Biver, E., & Paccou, J. (2023) · Calcified Tissue International · doi:10.1007/s00223-023-01150-8 · Cited by 50
Bone metabolism in diabetes: a clinician’s guide to understanding the bone–glucose interplay
Sheu, A., & White, C. (2024) · Diabetologia · doi:10.1007/s00125-024-06172-x · Cited by 55
Westberg-Rasmussen, S., Starup‐Linde, J., Hermansen, K., Holst, J. J., Hartmann, B., Vestergaard, P., & Gregersen, S. (2017) · Bone · doi:10.1016/j.bone.2017.01.027 · Cited by 50
Self-citationBone health in adults with obesity before and after interventions to promote weight loss
Paccou, J., & Compston, J. E. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00163-3 · Cited by 47
Skeletal Fragility in Type 2 Diabetes Mellitus
Starup‐Linde, J., Hygum, K., & Langdahl, B. L. (2018) · Endocrinology and Metabolism · doi:10.3803/enm.2018.33.3.339 · Cited by 47
Wen, B., Zhao, L., Zhao, H., & Wang, X. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6043 · Cited by 46
Dulaglutide mitigates inflammatory response in fibroblast-like synoviocytes
Zheng, W., Pan, H., Wei, L., Gao, F., & Lin, X. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.05.034 · Cited by 43
Tao, Y., Ge, G., Wang, Q., Wang, W., Zhang, W., Bai, J., Lin, J., Shen, J., Guo, X., Xu, Y., et al. (2019) · IUBMB Life · doi:10.1002/iub.2031 · Cited by 40
Li, X., Yang, L., & Chen, L. (2024) · International Journal of Endocrinology · doi:10.1155/2024/1785321 · Cited by 39
Chai, S., Liu, F., Yang, Z., Yu, S., Liu, Z., Yang, Q., & Sun, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.825417 · Cited by 39
Sass, M. R., Danielsen, A. A., Köhler‐Forsberg, O., Storgaard, H., Knop, F. K., Nielsen, M. Ø., Sjödin, A. M., Mors, O. N., Correll, C. U., Ekstrøm, C. T., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068652 · Cited by 42
Jing, M., Sun, J., Wu, J., & Zheng, X. (2019) · Europe PMC (PubMed Central) · Cited by 37
Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications
Guglielmi, V., Bettini, S., Sbraccia, P., Busetto, L., Pellegrini, M., Yumuk, V., Colao, A. M. L., Ghoch, M. E., & Muscogiuri, G. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00502-7 · Cited by 41
Glorie, L., D’Haese, P. C., & Verhulst, A. (2016) · Bone · doi:10.1016/j.bone.2016.08.009 · Cited by 37
Complex interplay among adiposity, insulin resistance and bone health
Ma, C., Tonks, K. T. T., Samocha‐Bonet, D., & Greenfield, J. R. (2018) · Clinical Obesity · doi:10.1111/cob.12240 · Cited by 37
Therapeutic strategies for type 2 diabetes mellitus in women after menopause
Paschou, S. Α., Marina, L., Spartalis, E. D., Anagnostis, P. G., Alexandrou, A. P., Goulis, D. G., & Lambrinoudaki, I. V. (2019) · Maturitas · doi:10.1016/j.maturitas.2019.05.003 · Cited by 45
A Pilot Study Showing Acute Inhibitory Effect of GLP‐1 on the Bone Resorption Marker CTX in Humans
Nissen, A. A., Marstrand, S. D., Skov‐Jeppesen, K., Bremholm, L., Hornum, M., Andersen, U. B., Holst, J. J., ROSENKILDE, M. M., & Hartmann, B. (2019) · JBMR Plus · doi:10.1002/jbm4.10209 · Cited by 36
Self-citationCheng, Y., Liu, P., Xiang, Q., Liang, J., Chen, H., Zhang, H., & Yang, L. (2022) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-022-05396-5 · Cited by 36
Hansen, M. S., Tencerová, M., Frølich, J. S., Kassem, M. S., & Frost, M. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12850 · Cited by 37
Nelson, L. W., Lee, M. H., Garrett, J. W., Pickhardt, S. G., Warner, J. D., Summers, R. M., & Pickhardt, P. J. (2024) · American Journal of Roentgenology · doi:10.2214/ajr.24.31805 · Cited by 35
Structure and Function of Bone Marrow Adipocytes
de Paula, F. J. A., & Rosen, C. J. (2017) · Comprehensive physiology · doi:10.1002/cphy.c170010 · Cited by 39
Pechmann, L. M., Pinheiro, F. I., Andrade, V. F. C., & Moreira, C. A. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01412-x · Cited by 35
Khaity, A. M., Al-dardery, N. M., Albakri, K. A., Abdelwahab, O. A., Hefnawy, M. T., Yousef, Y. S. A. H., Taha, R. E. W., Swed, S., Hafez, W., Hurlemann, R., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1153648 · Cited by 35
The Multiple Biological Functions of Dipeptidyl Peptidase-4 in Bone Metabolism
Qiu, Y., Fu, B., Luo, D., Wang, H., Cao, H., Chen, X., Tian, L., & Yu, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.856954 · Cited by 32
Anagliptin stimulates osteoblastic cell differentiation and mineralization
Dong, C., Yang, H. H., Wang, Y., Xu, Y. H., Li, D., Cao, Z., Ning, Y., & Zhang, C. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109796 · Cited by 32
Renner, S., Blutke, A., Streckel, E., Wanke, R., & Wolf, E. (2015) · The Journal of Pathology · doi:10.1002/path.4655 · Cited by 30
Alliances of the gut and bone axis
Hansen, M. S., & Frost, M. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.06.024 · Cited by 32
Liu, H., Xiao, H., Lin, S., Zhou, H., Cheng, Y., Xie, B., & Xu, D. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1372399 · Cited by 35
Hu, N., Gong, X., Yin, S., Li, Q., Chen, H., Li, Y., Li, F., Qing, L., Yang, J., Zhu, S., et al. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1647223 · Cited by 27
Eriksson, R., Broberg, B. V., Ishøy, P. L., Bak, N., Andersen, U. B., Jørgensen, N. R., Knop, F. K., & Ebdrup, B. H. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00781 · Cited by 26
Self-citationDiagnosing Osteoporosis in Diabetes—A Systematic Review on BMD and Fractures
Brandt, I. A. G., Starup‐Linde, J., Andersen, S. S., & Viggers, R. (2024) · Current Osteoporosis Reports · doi:10.1007/s11914-024-00867-1 · Cited by 28
Gut hormones and bone homeostasis: potential therapeutic implications
Bouvard, B., & Mabilleau, G. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01000-z · Cited by 26
Research progress of diabetic osteoporosis: a comprehensive review
Ma, X., & Zhang, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1595228 · Cited by 28
Harper, C., Pattinson, A. L., Fernando, H. A., Zibellini, J., Seimon, R. V., & Sainsbury, A. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0025 · Cited by 26
Refaie, A. F. A., Baldassini, L., Mondillo, C., Ceccarelli, E., Tarquini, R., Gennari, L., Gonnelli, S., & Caffarelli, C. (2024) · Calcified Tissue International · doi:10.1007/s00223-024-01240-1 · Cited by 26
Al-Mashhadi, Z. K., Viggers, R., Fuglsang-Nielsen, R., Vestergaard, P., Gregersen, S., & Starup‐Linde, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.882998 · Cited by 28
Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health
Egger, A., KRAENZLIN, M. E., & Meier, C. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0337-9 · Cited by 25
The effects of diabetes therapy on bone: A clinical perspective
Kheniser, K. G., Santos, C. M. P., & Kashyap, S. R. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.04.005 · Cited by 24
Bone Health in Patients With Type 2 Diabetes
Forner, P. M., & Sheu, A. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae112 · Cited by 25
Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes—A Systematic Review
Viggers, R., Rasmussen, N. H., & Vestergaard, P. (2023) · JBMR Plus · doi:10.1002/jbm4.10817 · Cited by 23
Akyay, Ö. Z., Cantürk, Z., Selek, A., Çetinarslan, B., Tarkun, İ., Çakmak, Y., & Baydemır, C. (2023) · Medicine · doi:10.1097/md.0000000000035394 · Cited by 25
Napoli, N., Incalzi, R. A., Gennaro, G., Marcocci, C., Marfella, R., Papalia, R., Purrello, F., Ruggiero, C., Tarantino, U., Tramontana, F., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.01.019 · Cited by 22
Jensen, S. B. K., Lundgren, J. R., Janus, C., Juhl, C. R., Olsen, L. M., Rosenkilde, M., Holst, J. J., Stallknecht, B. M., Madsbad, S., & Torekov, S. S. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031431 · Cited by 20
Self-citationKim, H., Choi, S., Gu, M., Ko, S., Kwon, J.-H., Han, J., Kim, J. H., & Kim, M. G. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3843 · Cited by 26
Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures
Liu, Y., Walzer, D., Schmitz, S. H., Shukla, A. P., Ma, X., Chirko, D., Pipia, I., Sathi, S., Shukairy, U., Greenberg, M. D., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag052 · Cited by 26
Zeng, Z., Fei, L., Yang, J., Zuo, J., Huang, Z., & Li, H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.783352 · Cited by 20
Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity
Karam, L. B., Mabilleau, G., & Paccou, J. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07664-1 · Cited by 23
Castillo, M. C. M., Martínez-Ramírez, M. J., Arroyo, R. S., Prieto, I., Segarra, A. B., Garrido‐Martínez, M., Santiago, P., & Delgado‐Rodríguez, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-50117-z · Cited by 19
Associations between Postprandial Gut Hormones and Markers of Bone Remodeling
Jensen, N., Clemmensen, K. K. B., Jensen, M. M., Pedersen, H., Færch, K., Díaz, L. J., Quist, J. S., & Størling, J. (2021) · Nutrients · doi:10.3390/nu13093197 · Cited by 19
Vasto, S., Amato, A., Proia, P., & Baldassano, S. (2022) · Biology · doi:10.3390/biology11020296 · Cited by 22
Huang, C., Mao, T., & Hwang, S. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s389964 · Cited by 19
Wu, Z., Deng, W., Ye, Y., Xu, J., Han, D., Zheng, Y., & Zheng, Q. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1378291 · Cited by 19
Diabetes management before, during, and after bariatric and metabolic surgery
Kheniser, K. G., & Kashyap, S. R. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.06.006 · Cited by 19
The Impact of Exercise on Bone Health in Type 2 Diabetes Mellitus—a Systematic Review
Viggers, R., Al-Mashhadi, Z. K., Fuglsang-Nielsen, R., Gregersen, S., & Starup‐Linde, J. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00597-0 · Cited by 19
Glucose-Lowering Drugs and Fracture Risk—a Systematic Review
Al-Mashhadi, Z. K., Viggers, R., Fuglsang-Nielsen, R., de Vries, F., van den Bergh, J. P., Harsløf, T., Langdahl, B. L., Gregersen, S., & Starup‐Linde, J. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00638-8 · Cited by 18
Maagensen, H., Larsen, J. R., Jørgensen, N. R., Fink‐Jensen, A., & Vilsbøll, T. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113670 · Cited by 18
Self-citationChen, H., Ma, K., Hsieh, P., Liou, Y., & Jong, G. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.195472 · Cited by 17
Fahim, S. A., Attia, Y. M., Messiha, A. A., Nabawy, A. Y., Refaat, F., & El-Maadawy, W. H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118731 · Cited by 21
Metadata
- Authors
- Iepsen, E. W., Lundgren, J. R., Hartmann, B., Pedersen, O., Hansen, T., Jørgensen, N. R., Jensen, J.-E. B., Holst, J. J., Madsbad, S., & Torekov, S. S.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Iepsen, Eva W.
- Torekov, Signe S.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-08
- Volume
- 100
- Issue
- 8
- Pages
- 2909-2917
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1934495549
- Cited by
- 193
- References
- 54
- Citations by year
- 2026: 16 · 2025: 39 · 2024: 21 · 2023: 15 · 2022: 16 · 2021: 9 · 2020: 11 · 2019: 24 · 2018: 15 · 2017: 10 · 2016: 9 · 2015: 8
- FWCI
- 14.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Danish Diabetes Academy
- Ministério da Ciência, Tecnologia e Inovação
- Novo Nordisk
- Copenhagen Graduate School for Nanoscience and Nanotechnology
- Faculty of Health and Medical Sciences, University of Western Australia
- Hvidovre Hospital
- Novo Nordisk Fonden (NNF14OC0009787)
- Det Sundhedsvidenskabelige Fakultet, Københavns Universitet
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, liraglutide, bone loss, bone formation, weight loss, obesity, obese women, bone mineral content, bone turnover markers, P1NP, C-terminal telopeptide of type I collagen, hypocaloric diet, weight maintenance, glucagon-like peptide-1, osteoporosis prevention
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Adolescent, Adult, Aged, Bone Resorption, Female, Humans, Middle Aged, Obesity, Osteogenesis, Weight Loss, Receptors, Glucagon, Caloric Restriction, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
